IL17F and B-cell chronic lymphocytic leukemia: When PBMCs were activated with anti-CD3/CD28 for 7 days in culture in the presence of a cocktail of Th17-promoting cytokines (Fig. 3a), the percentages of CD4+ T cells expressing IL-17F were significantly higher for CLL as compared to control PBMCs (p = 0.0136).